[go: up one dir, main page]

WO2019078634A2 - Composition pharmaceutique pour la prévention ou le traitement de la résistance à l'insuline ou du foie gras, comprenant une protéine ptp4a1 - Google Patents

Composition pharmaceutique pour la prévention ou le traitement de la résistance à l'insuline ou du foie gras, comprenant une protéine ptp4a1 Download PDF

Info

Publication number
WO2019078634A2
WO2019078634A2 PCT/KR2018/012322 KR2018012322W WO2019078634A2 WO 2019078634 A2 WO2019078634 A2 WO 2019078634A2 KR 2018012322 W KR2018012322 W KR 2018012322W WO 2019078634 A2 WO2019078634 A2 WO 2019078634A2
Authority
WO
WIPO (PCT)
Prior art keywords
ptp4a1
insulin resistance
protein
fatty liver
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/012322
Other languages
English (en)
Korean (ko)
Other versions
WO2019078634A3 (fr
Inventor
민정기
박종길
황병태
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of WO2019078634A2 publication Critical patent/WO2019078634A2/fr
Publication of WO2019078634A3 publication Critical patent/WO2019078634A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Definitions

  • the present invention relates to a pharmaceutical composition for the prevention or treatment of insulin resistance or fatty liver comprising PTP4A1 (protein tyrosine phosphatase type IV A1) protein or a polynucleotide encoding said PTP4A1 protein.
  • PTP4A1 protein tyrosine phosphatase type IV A1
  • Diabetes mellitus is a metabolic disorder in which the body does not produce sufficient insulin, or the cells are not responsive to the resulting insulin and high blood glucose is maintained.
  • Hyperglycemia in diabetes causes classic symptoms of polyuria (frequent urination), increased thirst, and bulimia.
  • Type 1 diabetes results from the failure of insulin production in the body and can be improved by immediate injectable treatment with insulin.
  • Type 1 diabetes is caused by the loss of insulin-producing beta cells in the islets of Langerhans in the pancreas, leading to insulin deficiency.
  • Type 2 diabetes is sometimes caused by insulin resistance, which is a condition in which cells fail to properly use insulin, in combination with absolute insulin depletion, and hyperglycemia is a disease that improves insulin sensitivity or reduces glucose production by the liver Can be improved by treating the drug.
  • Insulin resistance refers to a pathological condition in which cells lose adequate responsiveness by insulin.
  • insulin is secreted by glucose into the blood, and blood glucose is absorbed into cells by insulin and used as an energy source. That is, the level of blood sugar rises after the meal, thus stimulating cells of peripheral tissues (skeletal muscles and fat) to secrete insulin and actively take glucose from the blood as an energy source. Since blood glucose is used as an energy source, lipids stored in the body are not used as an energy source. However, the normal carbohydrate digestion process does not appear normally in the insulin resistant state.
  • beta cells in the pancreas secrete more insulin to maintain blood glucose homeostasis in order to lower blood glucose concentration.
  • insulin resistance does not allow an adequate amount of glucose to enter the liver, the liver is recognized to have low levels of glucose in the liver, thereby increasing glucose biosynthesis, which causes blood glucose to increase again. Therefore, in the state of persistent insulin resistance, even though the amount of insulin in the blood is increased, the blood glucose level is greatly increased and becomes a cause of metabolic disease.
  • the insulin resistance treatment method induces weight loss through dietary habits and lifestyle changes through exercise and exercise, thereby lowering the blood sugar level.
  • the main problem is that patients do not maintain such treatment continuously.
  • a hypoglycemic agent that lowers blood glucose metalformin, a kind of BIGOANID, thyazolidinediones such as pioglitazone and rosiglitazone, which activate PPARgamma, glucosidase inhibitors that delay the absorption of carbohydrates in the small intestine, , Sulfonylurea and non-sulfonylurea, alone or in combination with insulin, have been associated with problems such as weight gain, digestive disorders, cardiovascular disease, liver disease and hypoglycemia.
  • Fatty liver disease is defined as fatty liver when fat accounts for more than 10% of liver weight and is closely related to metabolic diseases such as obesity and diabetes. Fatty liver formation can be the cause of insulin resistance, and conversely, insulin resistance can cause fatty liver production.
  • the action of insulin in liver tissues can be broadly divided into the inhibition of glucose biosynthesis and the promotion of lipid biosynthesis. However, in the insulin-resistant state, only the inhibition of glucose biosynthesis is impaired and the lipid biosynthesis reaction is continuously activated, resulting in fatty liver formation.
  • Fatty liver disease can be classified according to the presence or absence of inflammation and fibrosis, and fatty liver accompanied by inflammation and fibrosis is called lipid hepatitis. Continuous fatty liver disease may ultimately lead to liver cirrhosis, which can lead to hepatic function impairment, and there is no urgent need for the development and research of therapeutic agents in the absence of appropriate therapeutic agents except for liver transplantation.
  • Patent Document 1 discloses a technique for treating insulin resistance or fatty liver using a black bean leaf extract.
  • PTP4A1 phosphatase of regenerating liver 1 (Pr1-1)
  • PTP4A1 phosphatase of regenerating liver 1 (Pr1-1)
  • PTP4A1 is a dual protein tyrosine dephosphorylation capable of eliminating phosphorylation of tyrosine residue and serine / threonine residue in 109 mammalian protein tyrosine dephosphorylating enzymes Belong to the enzyme group.
  • PTP4A1 is known to play an important role in cell growth and liver regeneration as an immediate early gene, but there is no report of PTP4A1 related to insulin resistance and fatty liver induction.
  • the present invention relates to a method for treating insulin resistance and fatty liver in which insulin resistance and insulin resistance which can substitute for these methods in order to solve the problems such as difficulties in continuous administration in the case of diet and side effects in chemotherapy, PTP4A1, a protein tyrosine dephosphorylase, is presented as a target molecule for the development of a preventive and therapeutic agent for fatty liver.
  • PTP4A1 a protein tyrosine dephosphorylase
  • one aspect of the present invention provides a pharmaceutical composition for preventing or treating insulin resistance or fatty liver comprising a protein tyrosine phosphatase type IV A1 (PTP4A1) protein or a polynucleotide encoding the PTP4A1 protein .
  • PTP4A1 protein tyrosine phosphatase type IV A1
  • Another aspect of the present invention provides a pharmaceutical composition for preventing or treating insulin resistance or fatty liver comprising a cell transfected with a polynucleotide encoding a PTP4A1 protein.
  • Another aspect of the present invention relates to a method for detecting PTP4A1 comprising: 1) measuring the expression level of PTP4A1 in a sample derived from a subject as an experimental group; 2) comparing the expression level of PTP4A1 in step 1) with the expression level of PTP4A1 in the control-derived sample; And 3) determining that the expression level of PTP4A1 in step 2) is lower than that of the control, determining that the risk of insulin resistance or fatty liver is high, and providing a protein detection method for providing information on insulin resistance or fatty liver diagnosis do.
  • Another aspect of the present invention is a method for treating a PTP4A1-expressing cell line, comprising: 1) treating a test substance with a PTP4A1 expressing cell line; 2) measuring the level of expression or activity of the PTP4A1 protein in the cell line treated with the test substance of step 1); And 3) screening the test substance for which the expression or activity level of the PTP4A1 protein of step 2) is increased compared to the control not treated with the test substance, comprising the step of screening the test substance for insulin resistance or fatty liver therapeutic candidate .
  • the PTP4A1 protein of the present invention When a polynucleotide-inserted vector encoding the PTP4A1 protein of the present invention was administered to a wild type mouse subjected to a high-fat diet, blood glucose level was lower than that of a control group not overexpressing PTP4A1, insulin resistance Is improved and the insulin sensitivity is restored. In addition, when PTP4A1 is overexpressed, the fat production is remarkably inhibited as compared with the control group in which PTP4A1 is not overexpressed. Therefore, the PTP4A1 protein of the present invention or a polynucleotide encoding the PTP4A1 protein can be used to improve insulin resistance or fatty liver.
  • Figure 1A is a graph showing the glucose tolerance test results of PTP4A1 deficient mice: WT; Wild-type mice, PTP4A1 -1-; PTP4A1 deficient mice, the same in the following figures.
  • Figure 1B is a graph showing the results of insulin resistance test of PTP4A1 deficient mice.
  • FIG. 2A is a graph showing blood glucose level of PTP4A1 deficient mice fed a high-fat diet.
  • FIG. 2B is a graph showing blood insulin levels in PTP4A1-deficient mice fed a high-fat diet.
  • FIG. 2c is a graph showing blood glucose levels when fasting diabetic PTP4A1 deficient mice were fasted: HFD (fast); Fasting is followed by fasting. In the following figures, fast is fasting.
  • FIG. 2d is a graph showing insulin levels in blood when fasting-fed PTP4A1-deficient mice were fasted.
  • Figure 2E shows the HOMA-IR results of PTP4A1 deficient mice with high fat diet.
  • FIG. 2f is a graph showing the results of glucose tolerance test of PTP4A1 deficient mice in high-fat diets.
  • FIG. 2g is a graph showing the results of insulin resistance test of PTP4A1-deficient mice that were fed a high-fat diet.
  • FIG. 3A shows the results of staining fat formed in liver tissue of PTP4A1-deficient mice that received high-fat diets.
  • Figure 3b shows the amount of triglyceride in liver tissue of PTP4A1 deficient mice fed high fat diet.
  • FIG. 4A shows the change in body weight after high-fat diet by injecting AAV-aat-PTP4A1 and AAV-aat-Control into PTP4A1 deficient mice, respectively.
  • Figure 4b shows the fasting blood glucose levels after high fat diet with AAV-aat-PTP4A1 and AAV-aat-Control injected into PTP4A1 deficient mice, respectively.
  • FIG. 4C shows the levels of insulin levels in the blood after high-fat diet by injecting AAV-aat-PTP4A1 and AAV-aat-Control into PTP4A1 deficient mice, respectively.
  • Figure 4d shows the glucose tolerance test results after high fat diet by injecting AAV-aat-PTP4A1 and AAV-aat-Control into PTP4A1 deficient mice, respectively.
  • Figure 4e shows the amount of triglyceride in liver tissue after high fat diet by injecting AAV-aat-PTP4A1 and AAV-aat-Control into PTP4A1 deficient mice, respectively.
  • FIG. 5A shows changes in body weight after high-fat diet by injecting AAV-aat-PTP4A1 and AAV-aat-Control into wild-type mice, respectively.
  • Figure 5b shows the fasting blood glucose levels after high fat diet by injecting AAV-aat-PTP4A1 and AAV-aat-Control into wild-type mice, respectively.
  • FIG. 5c shows the levels of insulin in the blood after high-fat diet by injecting AAV-aat-PTP4A1 and AAV-aat-Control into wild-type mice, respectively.
  • FIG. 5D shows results of glucose tolerance test after high-fat diet by injecting AAV-aat-PTP4A1 and AAV-aat-Control into wild-type mice, respectively.
  • FIG. 5E shows the amount of triglyceride in liver tissues after high-fat diet by injecting AAV-aat-PTP4A1 and AAV-aat-Control into wild-type mice, respectively.
  • FIG. 6 is an image showing the degree of suppression of lipogenesis in human hepatocyte from overexpressing PTP4A1.
  • PTP4A1 protein tyrosine phosphatase type IV A1 protein for the prevention or treatment of insulin resistance or fatty liver
  • An aspect of the present invention provides a pharmaceutical composition for preventing or treating insulin resistance or fatty liver comprising a PTP4A1 protein or a polynucleotide encoding the PTP4A1 protein.
  • 'insulin resistance' refers to a state resulting in an increase in blood glucose over a normal range not due to insulin deficiency.
  • 'fatty liver' is a disease that fat accumulates in hepatocytes and accounts for more than 10% of liver weight, and there are alcoholic fatty liver related to alcohol and nonalcoholic fatty liver which is not related to alcohol.
  • the fatty liver preferably means a non-alcoholic fatty liver.
  • " prophylactic &quot refers to a reduction in the risk of developing a disease or disorder, i.e., one or more clinical symptoms of the disease progress in a subject that is susceptible to or susceptible to disease, .
  • " treatment &quot refers to alleviating the disease or disorder, i.e., inhibiting or reducing the progression of the disease or one or more clinical symptoms thereof.
  • the PTP4A1 protein of the present invention comprises the amino acid sequence of SEQ ID NO: 1 (NP_035330.1) or the amino acid sequence of SEQ ID NO: 2 (NP_003454.1), and the PTP4A1 protein includes, Deletions, insertions, substitutions, or combinations of amino acid residues, or fragments thereof.
  • Amino acid exchange at the level of proteins and peptides that do not globally alter the activity of the PTP4A1 protein is known in the art. In some cases, it may be modified by phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, and the like.
  • the present invention includes a protein having substantially the same amino acid sequence as the protein comprising the amino acid sequence of SEQ ID NO: 1 or the amino acid sequence of SEQ ID NO: 2, a mutant thereof, or an active fragment thereof.
  • the substantially same protein means those having an amino acid sequence homology of not less than 80%, preferably not less than 90%, and most preferably not less than 95%, but is not limited thereto, and has homology of not less than 80% Activity is included in the scope of the present invention.
  • the polynucleotide encoding the PTP4A1 protein comprises the nucleotide sequence of SEQ ID NO: 3 (NM_011200.2) or the nucleotide sequence of SEQ ID NO: 4 (NM_003463.4, 1154-1675).
  • the present invention also encompasses a gene consisting of a nucleotide sequence substantially identical to a nucleotide sequence of SEQ ID NO: 3 or a nucleotide sequence of SEQ ID NO: 4, and a fragment thereof.
  • the term "gene comprising substantially the same base sequence” as used herein refers to those having 80% or more, preferably 90% or more, and most preferably 95% or more of sequence homology, but is not limited thereto, and 80% or more of the sequence homology And is not limited as long as it is expressed as PTP4A1 protein and maintains the function of preventing or treating insulin resistance or fatty liver.
  • Such base sequences may be short or double-stranded, and may be DNA molecules or RNA (mRNA) molecules.
  • the polynucleotide encoding the PTP4A1 protein may be inserted into a vector.
  • the recombinant vector of the present invention may further comprise a polynucleotide encoding PTP4A1 and a control sequence for transcription or translation thereof.
  • Especially important regulatory sequences among the regulatory sequences are those that regulate transcription initiation, such as promoters and enhancers. It may also contain regulatory sequences consisting of initiation codon, termination codon, polyadenylation signal, Kozak, signal sequence for enhancer, membrane targeting and secretion, IRES (Internal Ribosome Entry Site), and the like.
  • IRES Internal Ribosome Entry Site
  • Promoters to be introduced for the specific purpose of the recombinant virus include CMV promoter, RSV promoter and SV promoter derived from viruses that induce continuous gene expression. Promoters capable of inducing expression of genes only in a specific environment and operated by hormones A promoter containing the ERE induced, an insect hormone-promoted promoter, an antibiotic tetracycline-induced promoter, and the like. These promoters can be inserted into the viral genome in a manner suitable for the purpose of the objective genetic material.
  • the vector may further include a promoter that specifically expresses a polynucleotide encoding PTP4A1 in liver tissue, and is a liver-specific promoter capable of regulating the transcription of the PTP4A1 polynucleotide.
  • hAAT or SERPINA1 promoter for example, a human alpha1-antitrypsin (hAAT or SERPINA1) promoter (hereinafter referred to as hAAT promoter) (SEQ ID NO: 5), a human albumin (ALB) promoter (SEQ ID NO: 6), human thyroxine-binding globulin or SERPINA7 promoter (hereinafter referred to as hTBG promoter) (SEQ ID NO: 7), human apolipoprotein 8) (nt + 233 to -548) and human cytochrome P450 3A4 (human cytochrome P450 3A4 or CYP3A4) promoter (hereinafter referred to as hAPOA2 promoter) (SEQ ID NO: ) (SEQ ID NO: 9) (nt +55 to -365) can be used.
  • hAPOA2 promoter human alpha1-antitrypsin promoter
  • hAAT promoter can be used, but is not limited thereto.
  • the liver-specific promoter and the PTP4A1 polynucleotide are operatively linked and the PTP4A1 polynucleotide is expressed specifically in the liver rather than other tissues by introducing a vector into which the liver-specific promoter and the PTP4A1 polynucleotide are operatively linked And the efficiency of gene therapy can be enhanced.
  • the liver-specific promoter may be derived from another gene or any other animal species.
  • By “operably linked” is meant that when a gene is ligated downstream of the promoter sequence, the expression of the gene is ligated into a possible form.
  • the vector may be a linear DNA, a plasmid vector, a recombinant viral vector, which can be expressed in a human or animal cell
  • the recombinant virus may be a baculovirus, a vanishia virus, a retrovirus, an adenovirus, an adeno-associated virus, a herpes simplex virus And lentivirus, and preferably it may be an adeno-associated virus, but is not limited thereto.
  • Another aspect of the present invention provides a pharmaceutical composition for preventing or treating insulin resistance or fatty liver comprising a cell transfected with a polynucleotide encoding a PTP4A1 protein.
  • the vector may be introduced into the host cell in a manner well known to those of ordinary skill in the art. Methods of introduction include, but are not limited to, electroporation and lipofection, and methods known in the art can be selected.
  • the transduction may be stable or transient.
  • transient transduction involves vector expression in a particular cell in which the vector is not integrated into the host cell genome.
  • stable transduction may involve vector expression in a particular cell, wherein the vector is integrated into the host cell genome.
  • the pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, humans, and the like in various routes.
  • &Quot; Administration " in the present invention includes a method of delivering a pharmaceutical composition or medicament into a system of a subject or to a specific area within or above the subject.
  • Administration can be, for example, by intramuscular, parenteral, intravenous, intramuscular, subcutaneous, intradermal, intranasal, oral, percutaneous, intrauterine, intracerebroventricular or mucosal administration have. It may also be administered topically or systemically.
  • the pharmaceutical composition of the present invention may be administered together with one or more active ingredients exhibiting the same or similar functions.
  • one or more additional pharmaceutically acceptable carriers may be included.
  • the pharmaceutically acceptable carrier may be a mixture of saline, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components. If necessary, an antioxidant, Other conventional additives such as a bacteriostatic agent may be added.
  • the amount of a component selected from the group consisting of a PTP4A1 protein, a polynucleotide encoding a PTP4A1 protein, and a polynucleotide encoding a PTP4A1 protein, which is an effective ingredient in the administration is determined by the weight, age, sex, , Diet, administration time, administration method, excretion rate, target site and severity of disease.
  • the daily dose of the pharmaceutical composition of the present invention may be administered in an amount of 0.0001 to 100 mg / kg, preferably 0.001 to 30 mg / kg, once or several times per day.
  • the administration period may be from 1 day to 2 months, but may be administered unlimited until the prevention or therapeutic effect of the disease is manifested.
  • the protein When the PTP4A1 protein is contained as an effective ingredient in the pharmaceutical composition of the present invention, the protein may be contained in an amount of 0.0001 to 10% by weight, preferably 0.001 to 1% by weight, based on the pharmaceutical composition.
  • the protein preferably contains 10 3 to 10 12 IU (10 to 10 10 PFU), more preferably 10 5 to 10 10 IU.
  • the effective dose of the composition containing the polynucleotide encoding the PTP4A1 protein of the present invention as an active ingredient is 0.05 to 12.5 mg / kg in the case of the vector per 1 kg of body weight, 10 7 to 10 6 in the case of the recombinant virus, 10 11 viral particles (10 5 to 10 9 IU) / kg, preferably when the vector is 0.1 to 10 mg / kg, when the recombinant virus is 10 8 to 10 10 particles (10 6 to 10 8 IU) / Kg, and can be administered 2 to 3 times a day.
  • Such composition is not necessarily limited to this, and may vary depending on the condition of the patient and the severity of the disease.
  • Another aspect of the present invention relates to a method for detecting PTP4A1 comprising: 1) measuring the expression level of PTP4A1 in a sample derived from a subject as an experimental group; 2) comparing the expression level of PTP4A1 in step 1) with the expression level of PTP4A1 in the control-derived sample; And 3) determining that the expression level of PTP4A1 in step 2) is lower than that of the control, determining that the risk of insulin resistance or fatty liver is high, and providing a protein detection method for providing information on insulin resistance or fatty liver diagnosis do.
  • Diagnosis &quot in the context of the present invention refers to a subject based on observation, test or circumstances to identify a subject having a disease, disorder, or condition based on the presence of one or more indicators, such as a disease, disorder, Clinical or other evaluation of the condition of the subject.
  • sample in the present invention represents a collection of similar fluids, cells, or tissues separated from a subject.
  • the term " sample " refers to a body fluid (e.g., urine, serum, blood fluids, lymph, bile fluid, ascetic fluid, ocular fluids and fluids collected by bronchial washing and / , Ascites, tissue samples, or cells from a subject. It also includes tear drops, serum, cerebrospinal fluid, feces, sputum, and cell extracts.
  • the level of expression of PTP4A1 is determined by Western blotting, enzyme-linked immunosorbent assay (ELISA), immunohistochemical staining (IHC), immunoprecipitation and immunofluorescence And the method of measuring the protein expression level can be applied to the present invention without limitation.
  • Another aspect of the present invention is a method for treating a PTP4A1-expressing cell line, comprising: 1) treating a test substance with a PTP4A1 expressing cell line; 2) measuring the level of expression or activity of the PTP4A1 protein in the cell line treated with the test substance of step 1); And 3) screening the test substance for which the expression or activity level of the PTP4A1 protein of step 2) is increased compared to the control not treated with the test substance, comprising the step of screening the test substance for insulin resistance or fatty liver therapeutic candidate .
  • the 'test substance' refers to all substances that are expected to indirectly or directly induce a change in the amount of gene expression that occurs in cells.
  • the test substance of step 1) may be selected from the group consisting of natural compounds, synthetic compounds, RNA, DNA, polypeptides, enzymes, proteins, ligands, antibodies, antigens, bacteria or fungi metabolites and bioactive molecules, Not limited.
  • the expression level of the PTP4A1 protein in step 2) can be determined by Western blotting, enzyme-linked immunosorbent assay (ELISA), immunohistochemical staining (IHC), immunoprecipitation, Immunofluorescence and flow cytometry (FACS). Any method capable of measuring the protein expression level can be used without limitation in the present invention.
  • ELISA enzyme-linked immunosorbent assay
  • IHC immunohistochemical staining
  • FACS Immunofluorescence and flow cytometry
  • the activity level of the PTP4A1 protein in the step 2) can be measured by any one method selected from the group consisting of SDS-PAGE, immunofluorescence, enzyme immunoassay (ELISA), mass spectrometry and protein chip,
  • the present invention is not limited thereto.
  • mice were prepared.
  • the CRISPR system is a bacterial immune system that recognizes these fragments as DNA when invaded by viruses and plasmids, and then uses Cas 9 (CRISPR associated protein 9: RNA-guided DNA endonuclease enzyme), a nuclease Cut it out. This can be applied to the genome, and if it is recognizable by the guide RNA, which is a specific nucleotide sequence, the desired site can be cut and corrected.
  • Cas 9 CRISPR associated protein 9: RNA-guided DNA endonuclease enzyme
  • gRNA bicistronic expression vector
  • Cas9 and gRNA single guide RNA
  • gRNA was prepared by targeting PTP4A1.
  • the nucleotide sequences of gRNA, wild-type PTP4A1, and PTP4A1 KO are shown in Table 1 below.
  • the prepared pX330 vector was introduced into a embryonic stem cell through a microinjection technique to produce a KO (knock-out) mouse.
  • Glucose tolerance test was performed on each mouse. Glucose tolerance is measured by measuring the glucose level with time after glucose injection. The glucose tolerance is measured by measuring the glucose level in the blood, that is, the degree of glucose absorption. The higher the concentration of glucose in the blood, High. After fasting for 16 hours, the animals were fasted and fed with 2 g D-glucose / Kg of body weight. The blood glucose level was measured with Bayer breeze for 2 hours. In addition, insulin tolerance test (ITT) was also performed on each mouse. The mice were fasted for 6 hours and fasted.
  • ITT insulin tolerance test
  • the blood glucose level was measured with a glucose meter for 2 hours after intraperitoneal injection of 1 U insulin / kg of body weight (Bovine Insulin-Sigma # 10516) , PTP4A1 - deficient mice had higher fasting blood glucose and hyperglycemia than the control group, and the area under the Curve of Glucose (AUC) was higher than that of wild - type mice at the time of glucose loading. From this, it was found that glucose resistance was deteriorated when PTP4A1 deficiency (Fig. 1A). Regarding insulin resistance, PTP4A1-deficient mice were also found to be insulin sensitive because their blood glucose levels remained higher than those of the control group even when insulin was administered, and the area of blood glucose was higher than that of the control group (FIG. 1B ).
  • Insulin resistant mice lacking PTP4A1 (PTP4A1 - / - ) prepared in Example 1 were used as an experimental group and wild type mice (WT) were used as a control group.
  • WT wild type mice
  • Each mouse was given a high fat diet (60% fat, HFD) for 12 weeks to produce a nonalcoholic fatty liver disease model. After 5 and 12 weeks, blood glucose and insulin concentrations were measured , And the glucose tolerance and insulin resistance of the experimental group and the control group were evaluated in the same manner as the glucose tolerance test and the insulin resistance test of Example 1, respectively.
  • HOMA-IR levels were evaluated to evaluate insulin resistance.
  • HOMA-IR was calculated using the following equation.
  • HOMA-IR fasting insulin (uU / mL) fasting blood glucose (mg / dL) / 405
  • PTP4A1 - deficient mice had higher fasting blood glucose and hyperglycemia than the control group, and the area under the Curve of Glucose (AUC) was higher than that of the wild type mice. From this, it was found that glucose resistance was deteriorated when PTP4A1 deficiency (Fig. 2f). Regarding insulin resistance, it was also found that PTP4A1-deficient mice are insulin sensitive because their blood glucose levels are maintained higher than those of the control group even when insulin is administered, and the area of blood glucose is higher than that of the control group, indicating insulin resistance ).
  • Example 1-1 the hepatic disease model established by insemination of PTP4A1 deficient insulin resistant mice was sacrificed at week 12 and liver was extracted. Liver tissue was subjected to oil-red O lipid staining and H & E (hematoxylin and eosin) staining, and the level of lipid formation was assessed by quantifying the amount of lipid.
  • mice with high insulin resistance (PTP4A1 - / - ) fed with high fat diet had more fat staining and significantly higher hepatic triglyceride (hepatic TG) levels than the control group, (Figs. 3A and 3B).
  • Aat (SEQ ID NO: 5), which is a liver-specific gene for adeno-associated virus (AAV) in order to analyze the effect of PTP4A1 on liver tissue-specific expression on insulin signaling and resistance, Were used to prepare the AAV-aat-PTP4A1 vector.
  • PTP4A1 uses mouse-derived mPTP4A1 CDS nucleotide sequence (NM_011200.2) (SEQ ID NO: 1), which encodes the mPTP4A1 amino acid sequence of SEQ ID NO: 3.
  • AAV8.2-hAAT-Flag-mPTP4A1 was constructed by double infecting insect Sf9 cells with rBV-inCap8.2-inRepOpt (V105) and rBV-hAAT-Flag-mPTP4A1 (KB22).
  • the AAV8.2-hAAT-intron vector was also constructed by double infecting insect Sf9 cells with rBV-inCap8.2-inRepOpt (V105) and rBV-hAAT-intron (KB23).
  • the vector was purified by using a CsCl supernatant centrifuge twice.
  • AAV-aat-PTP4A1 vector was injected into a PTP4A1-deficient mouse in a high-fat diet as in Example 2.
  • AAV-aat-Control was injected into PTP4A1 deficient mice with high-fat diets.
  • the prepared vector was injected with 2 ⁇ 10 11 AAV through mouse tail vein injection. After induction of PTP4A1 expression, body weight, glucose, glucose tolerance and insulin resistance were evaluated. In addition, the amount of neutral lipids was quantified to evaluate the degree of fatty liver formation.
  • ATP-aat-Control-treated mice were fed a high-fat diets containing AAV-aat-PTP4A1 and AAV-aat-Control.
  • -PTP4A1 injected group showed significantly lower neutral lipid levels than the control group AAV-aat-Control injected group (Fig. 4e))
  • AAV-aat-PTP4A1 and AAV-aat-Control were respectively injected into wild type mice to prepare test mice and control mice, and the insulin resistance was evaluated after high-fat diet. After the experiment was conducted in the same manner as in Example 3, except that the mice used were different, the degree of insulin resistance improvement was evaluated.
  • AAV-aat-PTP4A1 injection group and control AAV-aat-Control injection group were administered to the wild-type mice, respectively. There was no difference in body weight when the mice were fed a high-fat diet (Fig. 5A)
  • One group showed significantly lower fasting blood glucose levels (Figure 5b) and significantly lower blood insulin levels than the control group AAV-aat-Control ( Figure 5c). Also, glucose resistance was significantly improved by the glucose resistance test (Fig. 5d).
  • ATP-aat-PTP4A1 was injected into the wild-type mouse and the AAV-aat-Control injected group.
  • the results of biochemical analysis of neutral lipid in the liver were compared with those of AAV-aat-PTP4A1 (Fig. 5e), the neutral lipid level was lower than that of the control group, AAV-aat-Control.
  • ATP-aat-PTP4A1 and AAV-aat-control vector prepared in Example 3 were transfected into HepG2 hepatocyte (ATCC; HB-8065), and then PTP4A1 was overexpressed to induce lipogenesis by treatment with oleate. And the degree of suppression of fat production was confirmed.
  • BSA-OA bovine serum albumin conjugated oleic acids, 400 ⁇ M
  • DMEM fetal bovine serum albumin conjugated oleic acids, 400 ⁇ M

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement de la résistance à l'insuline ou du foie gras, comprenant une protéine PTP4A1 ou un polynucléotide codant pour la protéine PTP4A1. La surexpression de la protéine PTP4A1 a pour effet d'atténuer la résistance à l'insuline et de supprimer la production de foie gras de sorte que la protéine PTP4A1 selon la présente invention peut être efficacement utilisée à titre d'agent thérapeutique dans le domaine des syndromes métaboliques.
PCT/KR2018/012322 2017-10-18 2018-10-18 Composition pharmaceutique pour la prévention ou le traitement de la résistance à l'insuline ou du foie gras, comprenant une protéine ptp4a1 Ceased WO2019078634A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0135408 2017-10-18
KR1020170135408A KR102496229B1 (ko) 2017-10-18 2017-10-18 Ptp4a1 단백질을 포함하는 인슐린 저항성 또는 지방간의 예방 또는 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
WO2019078634A2 true WO2019078634A2 (fr) 2019-04-25
WO2019078634A3 WO2019078634A3 (fr) 2019-06-20

Family

ID=66174150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012322 Ceased WO2019078634A2 (fr) 2017-10-18 2018-10-18 Composition pharmaceutique pour la prévention ou le traitement de la résistance à l'insuline ou du foie gras, comprenant une protéine ptp4a1

Country Status (2)

Country Link
KR (1) KR102496229B1 (fr)
WO (1) WO2019078634A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102216646B1 (ko) * 2018-11-23 2021-02-17 차의과학대학교 산학협력단 중간엽 줄기세포를 포함하는 지방 생성을 억제하기 위한 조성물
KR20240177783A (ko) * 2023-06-19 2024-12-30 (주) 플라바이오로직스 펩타이드 도입에 따른 중간엽 줄기세포의 제조방법 및 치료용 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558261A4 (fr) * 2002-10-31 2008-06-04 Israel State Compositions de quinazolinone destinees a reguler l'expression genetique dans des processus pathologiques
EP2177615A1 (fr) * 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Procédé pour une identification large du génome de séquences régulatrices de l'expression et utilisation de gènes et de molécules dérivées pour le diagnostic et le traitement de maladies métaboliques et/ou tumorales
KR20160000041A (ko) * 2014-06-23 2016-01-04 주식회사 바이오포트코리아 인삼 열매 추출물을 유효성분으로 포함하는 당뇨병 또는 당뇨 합병증 예방, 개선 또는 치료용 조성물
KR101834857B1 (ko) * 2015-01-05 2018-03-07 서울대학교산학협력단 제2형 당뇨병의 조기 진단을 위한 단백질 바이오 마커
CN107949394B (zh) 2015-08-19 2021-07-30 韩国生命工学研究院 黑豆叶提取物在制备用于预防或治疗代谢综合征的药物中的用途

Also Published As

Publication number Publication date
KR20190043397A (ko) 2019-04-26
WO2019078634A3 (fr) 2019-06-20
KR102496229B1 (ko) 2023-02-06

Similar Documents

Publication Publication Date Title
Castagliuolo et al. Neurokinin-1 (NK-1) receptor is required in Clostridium difficile-induced enteritis.
WO2018074682A1 (fr) Peptide à efficacité anti-obésité et anti-diabétique et son utilisation
Cho et al. Protective effect of boiled and freeze-dried mature silkworm larval powder against diethylnitrosamine-induced hepatotoxicity in mice
WO2019078634A2 (fr) Composition pharmaceutique pour la prévention ou le traitement de la résistance à l'insuline ou du foie gras, comprenant une protéine ptp4a1
WO2020189970A1 (fr) Composition pharmaceutique pour prévenir ou traiter une stéatose hépatique non alcoolique, comprenant tcf7l2 en tant que composant efficace
Sujishi et al. Sitagliptin can inhibit the development of hepatic steatosis in high-fructose diet-fed ob/ob mice
Zheng et al. A novel agonist of PPAR-γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance
Zaidalkilani et al. The beneficial and detrimental effects of prolactin hormone on metabolic syndrome: A double‐edge sword
Tambo et al. The microbial hypothesis: contributions of adenovirus infection and metabolic endotoxaemia to the pathogenesis of obesity
WO2023140664A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de la fibrose hépatique induite par la stéatohépatite non alcoolique, contenant, en tant que principe actif, un inhibiteur d'expression de la lipocaline 2 ou un récepteur de celle-ci
US20100168014A1 (en) Screening method
Otsuki et al. Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats
WO2019124803A1 (fr) Composition comprenant un extrait de selaginella rossii warb. ou des fractions de celui-ci pour la prévention ou le traitement de syndromes métaboliques
WO2019203555A1 (fr) Composition, comprenant une protéine progranuline, pour la prévention ou le traitement d'une maladie hépatique
JP2003113111A (ja) 糖尿病治療用医薬
Yan et al. Bioreactor-based stem cell therapy for liver fibrosis
EP2140874A1 (fr) Médicament contre l'hépatite aiguë ou agent préventif/médicament contre l'hépatite fulminante
WO2013015611A2 (fr) Composition pour la prévention de dommage de chondrocytes et la régénération de ceux-ci, comprenant un hydrolysat de levure comme principe actif
Miyasaka et al. Luminal feedback regulation, monitor peptide, CCK-releasing peptide, and CCK receptors
WO2018016806A1 (fr) Méthode de traitement de la stéatose hépatique ou de la stéatose hépatique non alcoolique à l'aide de l'enzyme de clivage de la 2-monoacylglycérol
Wu et al. Astaxanthin attenuates hepatic damages and mitochondrial dysfunction in nonalcoholic fatty liver disease by regulating the fgf21/pgc-1α pathway
WO2025225968A1 (fr) Composition pour la prévention ou le traitement d'une maladie intestinale inflammatoire
EP4360643A1 (fr) Peptides dérivés de socs1 destinés à être utilisés dans le traitement de maladies hépatiques
WO2022039571A1 (fr) Culture mycélienne de nouvelle souche de porostereum sp. (kctc18837p) et composition la comprenant en tant que principe actif pour la prévention ou le traitement du diabète sucré
US20160002316A1 (en) Serpins: methods of therapeutic beta-cell regeneration and function

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18868993

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18868993

Country of ref document: EP

Kind code of ref document: A2